Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.58 |
| ▸ | CA1 | P00915 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28192908 | 1.00 | CA2 (0.58) | CA2CA1MAPK1ZDHHC7MAPT | |
| SCHEMBL9081169 | 1.00 | CA2 (0.58) | CA2CA1MAPK1ZDHHC7MAPT | |
| SCHEMBL6116357 | 0.98 | CA2 (0.60) | CA2CA1MAPK1ZDHHC7MAPT | |
| SCHEMBL7222901 | 0.92 | CA2 (0.58) | CA2CA1MAPK1ZDHHC7MAPT | |
| SCHEMBL7217255 | 0.92 | CA2 (0.58) | CA2CA1MAPK1ZDHHC7MAPT | |
| SCHEMBL7219194 | 0.92 | CA2 (0.58) | CA2CA1MAPK1ZDHHC7MAPT | |
| SCHEMBL7223920 | 0.92 | CA2 (0.58) | CA2CA1MAPK1ZDHHC7MAPT | |
| SCHEMBL7218993 | 0.92 | CA2 (0.58) | CA2CA1MAPK1ZDHHC7MAPT | |
| SCHEMBL3403953 | 0.92 | CA2 (0.58) | CA2CA1MAPK1ZDHHC7MAPT | |
| SCHEMBL3454037 | 0.92 | CA2 (0.58) | CA2CA1MAPK1ZDHHC7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450301-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180177760-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N-SUBSTITUTED-2-AMINOTETRALINS, AND RELATED DOSAGE FORMS | SPRIASO LLC (US) | 2018-06-28 | — | — | US | disclosed |
| US-9956201-B2 | Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms | SPRIASO LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9362595-B2 | Nonaqueous electrolytic solution and energy storage device using same | UBE INDUSTRIES, LTD. (JP) | 2016-06-07 | — | — | US | disclosed |
| US-20160015684-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS | SPRIASO LLC | 2016-01-21 | — | — | US | disclosed |
| US-20160016887-A1 | Methods of treating a subject using bioreversible derivatives of hydroxy n-substituted-2-aminotetralins | SPRIASO LLC | 2016-01-21 | — | — | US | disclosed |
| US-20140030609-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND ENERGY STORAGE DEVICE USING SAME | UBE INDUSTRIES, LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| CN-103477492-A | Non-aqueous electrolyte solution and electricity-storage device using same | UBE INDUSTRIES | 2013-12-25 | — | — | CN | disclosed |
| US-6667285-B1 | Branched-chain carboxylic acid monoalkyl ester with outstanding hydrolytic stability | NEW JAPAN CHEMICAL CO., LTD. (JP) | 2003-12-23 | — | — | US | disclosed |
| EP-1225213-A1 | LUBRICATING OIL FOR REFRIGERATOR, HYDRAULIC FLUID COMPOSITION FOR REFRIGERATOR AND METHOD FOR LUBRICATION OF REFRIGERATOR | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 2002-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016887-A1 | Methods of treating a subject using bioreversible derivatives of hydroxy n-substituted-2-aminotetralins | SLC7A1, CYP2D6, SLC19A1 | CA2 1438/4885CA1 2522/4885MAPK1 4794/4885 |
| US-20160015684-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS | SLC7A1, CYP2D6, CYP3A7 | CA2 1820/4885CA1 3239/4885MAPK1 4724/4885 |
| US-20180177760-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N-SUBSTITUTED-2-AMINOTETRALINS, AND RELATED DOSAGE FORMS | SLC7A1, CYP2D6, CYP3A7 | CA2 1710/4885CA1 3251/4885MAPK1 4652/4885 |
| US-10450301-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, AIFM1, BCL2 | CA2 4216/4885CA1 3532/4885MAPK1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.